Paper Details

  1. Home
  2. Paper Details

Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma.

Author: AbadaPaolo, AlencarAlvaro J, BalbasMinna, CheahChan Y, EyreToby A, FenskeTimothy S, FlinnIan, GersonJames N, Hernandez-IlizaliturriFrancisco, IzutsuKoji, JurczakWojciech, KohYoungil, KumarAnita, LamannaNicole, Lech-MarandaEwa, LewisDavid, MaShuo, MaddocksKami, MatoAnthony R, MunirTalha, NagaiHirokazu, NairBinoj, PatelKrish, RhodesJoanna, SeymourJohn F, ShahNirav N, TamConstantine S, TessoulinBenoit, TsaiDonald E, UjjaniChaitra S, WalgrenRichard A, WangChunxiao, WangMichael L, WangYucai, ZelenetzAndrew D, ZhaoJunjie, ZinzaniPier Luigi

Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This phase I/II trial investigated the safety and efficacy of pirtobrutinib, a noncovalent Bruton tyrosine kinase inhibitor (BTKi), in patients with covalent BTKi-pretreated mantle-cell lymphoma (MCL). Pirtobrutinib demonstrated durable efficacy with an overall response rate of 57.8% and a median duration of response of 21.6 months. Pirtobrutinib was well-tolerated with low rates of treatment discontinuation due to toxicity.
Paper Details　
Original Abstract of the Article :
PURPOSE: Pirtobrutinib is a highly selective, noncovalent (reversible) Bruton tyrosine kinase inhibitor (BTKi). We report the safety and efficacy of pirtobrutinib in patients with covalent Bruton tyrosine kinase inhibitor (cBTKi) pretreated mantle-cell lymphoma (MCL), a population with poor prognosi...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10461952/

データ提供：米国国立医学図書館（NLM）

Pirtobrutinib: A Novel Treatment Option for Mantle-Cell Lymphoma

Mantle-cell lymphoma (MCL) is a type of non-Hodgkin lymphoma with a challenging prognosis, especially after treatment with covalent Bruton tyrosine kinase inhibitors (cBTKIs). This study investigates the safety and efficacy of pirtobrutinib, a novel, noncovalent Bruton tyrosine kinase inhibitor, in patients with cBTKI-pretreated MCL.

A Promising Alternative for MCL Patients

The results are encouraging. Pirtobrutinib demonstrated significant efficacy in this challenging patient population, with an overall response rate of 57.8%, including 20% complete responses. The median duration of response was 21.6 months. This suggests that pirtobrutinib can provide durable benefit for patients who have failed prior cBTKI therapies.

Navigating the Desert of Treatment Options: Hope for MCL Patients

These findings offer hope for individuals with MCL. The study highlights the importance of exploring new treatment options, especially for patients who have exhausted conventional therapies. Pirtobrutinib represents a potential oasis in the desert of treatment options for MCL patients, offering a path towards better outcomes.

Dr.Camel's Conclusion

This research is a beacon of hope in the desert of cancer treatment. Pirtobrutinib offers a promising alternative for patients with MCL who have limited options. It’s like discovering a hidden spring in the middle of the desert – a source of hope and renewal for those who need it most.

Date :
  1. Date Completed 2023-08-18
  2. Date Revised 2023-12-13
Further Info :

Pubmed ID

37192437

DOI: Digital Object Identifier

PMC10461952

Related Literature

Article Analysis
・Effects of pirtobrutinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.